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Transcriptome Profiling Identifies HMGA2 as a
Biomarker of Melanoma Progression and Prognosis
Leon Raskin1, Douglas R. Fullen2,3, Thomas J. Giordano3,4, Dafydd G. Thomas3, Marcus L. Frohm2,
Kelly B. Cha2, Jaeil Ahn5, Bhramar Mukherjee5, Timothy M. Johnson2 and Stephen B. Gruber4,6,7,8
The genetic alterations contributing to melanoma pathogenesis are incompletely defined, and few independent
prognostic features have been identified beyond the clinicopathological characteristics of the primary tumor. We
used transcriptome profiling of 46 primary melanomas, 12 melanoma metastases, and 16 normal skin (N) samples
to find genes associated with melanoma development and progression. Results were confirmed using
immunohistochemistry and real-time PCR and replicated in an independent set of 330 melanomas using AQUA
analysis of tissue microarray (TMA). Transcriptome profiling revealed that transcription factor HMGA2, previously
unrecognized in melanoma pathogenesis, is significantly upregulated in primary melanoma and metastases
(P-values¼ 1.2 10 7 and 9 10 5) compared with N. HMGA2 overexpression is associated with BRAF/NRAS
mutations (P¼ 0.0002). Cox proportional hazard regression model and log-rank test showed that HMGA2 is
independently associated with disease-free survival (hazard ratio (HR)¼ 6.3, 95% confidence interval (CI)¼
1.8–22.3, P¼ 0.004), overall survival (OS) (stratified log-rank P¼ 0.008), and distant metastases–free survival
(HR¼ 6.4, 95% CI¼ 1.4–29.7, P¼ 0.018) after adjusting for American Joint Committee on Cancer (AJCC) stage
and age at diagnosis. Survival analysis in an independent replication TMA of 330 melanomas confirmed the
association of HMGA2 expression with OS (P¼ 0.0211). Our study implicates HMGA2 in melanoma progression
and demonstrates that HMGA2 overexpression can serve as an independent predictor of survival in melanoma.
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INTRODUCTION
The incidence of melanoma in the United States continues to
increase; melanoma causes three out of four deaths due to
skin cancer (Hayat et al., 2007; Siegel et al., 2012). Early-stage
melanoma is frequently curable, in contrast to the poorer
prognosis of melanoma with regional lymph node involvement
and the dismal outcome of widely metastatic disease. The
molecular alterations contributing to the pathogenesis of
melanoma are incompletely defined, and few independent
prognostic features have been identified beyond the clinical
and pathological characteristics of the primary tumor.
Melanoma is generally resistant to chemotherapeutic and
immunological treatments, and the efficacy of adjuvant
therapy of melanoma is modest at best. The contribution of
these therapies to overall survival (OS) of melanoma patients is
limited. Although the management of melanoma is rapidly
changing because of a better understanding of molecular
heterogeneity and introduction of novel targeted therapies,
new biomarkers can offer opportunities to develop prognostic
models and new therapeutic targets.
Clinical trials for melanoma currently concentrate on rational
drug development with several classes of drugs, including kinase
inhibitors that target BRAF*V600, VEGF/PDGF receptors, and
mutated KIT, as well as drugs that target cell survival signaling
pathways involving MEK, PI(3)K, or PTEN/AKT (Gray-Schopfer
et al., 2007; Nikolaou et al., 2012; Woodman et al., 2012).
Identification of new signaling pathways in melanoma initiation
and progression opens new opportunities for targeted melanoma
therapy. In 2011, vemurafenib and ipilimumab became the
first drugs approved by the Food and Drug Administration for
the treatment of metastatic melanoma patients with BRAF
V600 mutations and inoperable late-stage melanoma, respec-
tively (Curti and Urba, 2012; Woodman et al., 2012).
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Microarray analysis of gene expression has been used to
reveal sets of coregulated genes and unpredicted biological
relationships in many cancer types, including melanoma
(reviewed by Hoek (2007); Schramm et al. (2012)). Studies
with different tumor source (cell lines or fresh tumors),
microarray platform, and hypotheses considered reported
gene expression profiles in melanoma (Bittner et al., 2000;
Hoek et al., 2004; Pavey et al., 2004; Bloethner et al., 2005;
de Wit et al., 2005; Haqq et al., 2005; Mandruzzato et al.,
2006; Winnepenninckx et al., 2006; Jaeger et al., 2007;
Kauffmann et al., 2008; Riker et al., 2008; Conway et al.,
2009). As demonstrated in a meta-analysis of melanoma gene
expression studies, the source of studied material (cell lines or
tissue) may affect the list of differentially expressed genes
(Hoek, 2007). Partial reporting of gene lists with different
significance thresholds also contributes to discordant lists.
Although cell lines provide a homogenous and reproducible
source of melanoma cells, tissue samples may generate results
more relevant to clinical use.
Our study used gene expression profiling of primary mela-
nomas, regional and distant melanoma metastases (MM), and
normal skin (N) samples to find novel genes associated with
melanoma development and progression. We report genes
differentially expressed in primary melanoma and MM, includ-
ing new and previously reported melanoma genes. Further-
more, we demonstrate that transcription factor HMGA2 is
highly overexpressed in melanoma, is strongly associated with
regional and distant metastases, and serves as an independent
predictor of disease-free survival (DFS) and OS in melanoma.
RESULTS
Sample characteristics for expression microarray and analysis of
BRAF/NRAS mutations
Frozen samples were collected from 421 patients out of 7,959
patients treated at the University of Michigan Multidisciplinary
Melanoma Clinic. Samples with sufficiently large lesions were
selected for the study (n¼ 129); this includes frozen tissue
from 67 primary melanomas, 20 MM, and 42 N samples
collected from 102 patients. There were 27 paired samples
from the same excision (primary melanoma-N), and two
patients had two distinct primary melanomas. Clinicopatho-
logical characteristics of those samples with microarray data
that passed quality control (46 primary melanomas, 12 MM,
and 16 N samples) were not significantly different from
collected samples (Table 1). Median follow-up was 4 years
in primary melanomas.
Primary melanomas (n¼ 46) had 20 BRAF-mutated samples
(L597R (n¼ 1), L597S (n¼ 1), V600R (n¼ 1), V600K (n¼2),
and V600E (n¼ 15)), 6 NRAS-mutated samples (Q61K (n¼1),
Q61R (n¼ 3), Q61L (n¼2)), and 20 samples without muta-
tions in BRAF or NRAS (Figure 1a). Among MM (n¼12), eight
had mutations in BRAF (V600K (n¼1) and V600E (n¼ 7)), two
had NRAS mutations (Q61K (n¼ 2)), and two samples had no
mutations in BRAF/NRAS. BRAF and NRAS mutations were
mutually exclusive in all samples. The observed frequency of
BRAF/NRAS mutations in primary melanoma (56%) and MM
(83%) is consistent with a previous report (Poynter et al.,
2006). Mean mutant to wild-type signal ratio was 1.91 for
BRAF and 1.05 for NRAS mutations demonstrating a low level
of sample contamination (Supplementary Table S2 online).
Gene expression differences between primary melanoma, MM,
and N
Principal component analysis showed that, although the N
and metastases could be distinguished by expression profiles,
the expression levels of primary melanomas were heteroge-
nous, and principal components were spread across the data
matrix (Supplementary Figure S1 online). We effectively
separated N and melanoma using gene expression analysis
(Supplementary Figure S2 online). Three melanomas in situ
clustered with N.
Differentially expressed genes were identified in four com-
parisons: primary cutaneous and MM versus N (PCMþMM vs.
N); PCM versus N; MM versus N; and MM versus PCM
(Supplementary Table S1 online). Compared with N, upregu-
lated gene lists in both PCM and MM were significantly (P-
value o1.33E 06) enriched with genes related to nervous
system development. The list of genes upregulated in PCM,
unlike MM, was significantly (P-value o0.0023) enriched with
melanocyte development genes. Upregulated genes in MM
related to mitosis, cell division, and cell cycle (P-value
o2.53E09); cell adhesion (P-value o4.36E07); immune
response (P-value o4.29E06); and cell motility and migra-
tion (P-valueo0.0125). In MM versus PCM, upregulated genes
were associated with transcription and gene expression (P-value
o1.71E04). In all comparisons, downregulated genes were
(P-value o4.09E06) enriched with epidermis development,
keratinization, and cell adhesion genes (P-value o3.03E 04).
In PCM versus N, we found upregulated melanoma stem
cell markers (ABCB5 and ABCC2), melanoma-associated
tumor antigens (MAGEA2, PRAME, ARMC9, and SLC45A2),
melanoma progression genes (MIA, GDF15, SPP1, KMO, and
S100B), melanocyte development and melanin biosynthesis
genes (CITED1, SILV, MLANA, TYR, MITF, PAX3, and TFEC),
cell cycle progression genes (S100A1), apoptotic genes
(BCL2A1, FAIM3), oncogenic transcription factors (HMGA2,
GDF15, HOXD13, and LZTS1), and cell adhesion gene
(NRP2). Obviously, the genes related to keratinocyte differ-
entiation (KRT25, KRT71, and KRT85) appeared downregu-
lated in PCM as compared with N. MM versus N comparison
showed upregulated melanoma-associated tumor antigens
(AKT3 and ARMC9), melanoma progression genes (MIA,
SPP1, KMO, and IL8), melanocyte development and melanin
biosynthesis genes (CITED1 and PAX3), cell cycle progression
genes (BUB1), apoptotic genes (BCL2A1), oncogenic tran-
scription factors (HMGA2, HOXD13, ETV1, and ETV5), and
cell adhesion genes (ADAM10 and NRP2). As expected,
downregulated genes in MM versus N were involved in
keratinocyte differentiation and epidermal development (ker-
atins, sciellin (SCEL), and cystatin (CST6)). Some cell adhesion
genes (DSC3, DSG1, and LY6D), tumor suppressors (kallik-
reins and CLCA2), and cell cycle and apoptosis-regulating
genes (FGFR2, BNIPL, and TNS4) were downregulated in
MM. Several transcription factors, including ETV1, and a
melanoma-associated antigen SPP1 were upregulated in MM
as compared with PCM.
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To identify new melanoma-associated genes, we focused
on the top tenth percentile of upregulated genes with the
highest fold change (FC42.68) in PCMþMM versus N
(Supplementary Table S2 online). Within this group, we
observed previously characterized melanoma-specific markers
(MAGEA3, PRAME, SLC45A2, and SPP1), anti-apoptotic
BCL2A1, actin regulator PHACTR1, SPRYD5 involved in cell
growth and differentiation, TUBB4 involved in cell migration,
and finally the transcription factor HMGA2, which was the only
gene associated with melanoma survival as described below.
HMGA2 expression in N, primary melanoma, and MM
Analysis of relative expression of HMGA2 in the microarray
demonstrated overexpression (higher than median¼ 6.29) in
57% of primary melanomas and 83% of MM compared with
N (Figure 1a). Expression of HMGA2 in N was lower than
median in 94% of samples. One N sample (N307) that had
higher than median expression of HMGA2 was also clustered
with melanoma in the supervised cluster analysis. It is
important to note that the HMGA2 expression in N sample
N307 was similar to the expression in MEL307 melanoma
sample from the same patient.
In the discovery set, we validated the microarray HMGA2
expression using quantitative real-time reverse transcriptase–
PCR (RT-PCR) (Figure 1b). Pearson’s correlation coefficient
was 0.84 between the expression of HMGA2 microarray
probe 208025_s_at and HMGA2 expression from real-time
RT-PCR (Po0.0001). To ensure real-time RT-PCR validity, we
also ran RT-PCR for SPP1, the well-known melanoma-specific
marker (Pearson’s coefficient for 1568574_x_at and SPP1 in
RT-PCR was 0.84 (Po0.0001)).
Continuous HMGA2 expression in the microarray was
significantly associated with BRAF/NRAS mutations in PCM
and MM (odds ratio (OR)¼3.4, 95% confidence interval
(CI)¼1.2–9.3, P¼0.017). We confirmed this association in
RT-PCR (OR¼ 2.38, 95% CI¼ 1.3–4.2, P¼ 0.003) and vali-
dated it using melanoma cell lines with known BRAF/NRAS
mutations. Melanoma cell lines A2058 and SK-MEL-31,
heterozygous for BRAF*V600E, and A375 cell lines, homo-
zygous for BRAF*V600E, showed overexpressed HMGA2
comparable to melanoma samples. The CHL-1 without BRAF
and NRAS mutations had no detectable expression of HMGA2
(Supplementary Figure S3 online).
We also found association of continuous HMGA2 expres-
sion with sentinel lymph node status (OR¼2.7, 95% CI¼1.1–
6.5, P¼0.034).
Immunohistochemical staining of HMGA2 in N, benign nevi, and
melanoma
We validated results of HMGA2 expression at the protein level
using immunohistochemical staining on 9 N samples, 41
melanoma samples, and 7 MM that were used for the
expression microarray (Figures 1c and 2). All N samples
demonstrated no nuclear staining. Melanomas with overex-
pressed HMGA2 had strong nuclear staining. Melanomas with
moderate HMGA2 expression were heterogenous, possessing
a variable number of cells with moderate nuclear staining. Six
out of seven MM had nuclear HMGA2 staining. Twenty
benign nevi showed no nuclear staining against HMGA2.
Effect of HMGA2 expression on survival end points in melanoma
To evaluate the correlation of HMGA2 overexpression with
survival of melanoma patients, we categorized expression
Table 1. Clinicopathological characteristics of study
samples
Characteristics1
Discovery set
(n¼74)
Replication
set
(n¼ 330) P-value
Normal tissue (n) 16 —
Primary melanoma (not metastatic) (n) 46 330
Melanoma metastases (n) 12 —
Mean age, years (range)2 59.4 (20–92) 54.5 (48–87) 0.0072
Median Breslow thickness, mm
(range)
3 (0.6–19) 2.45 (0.25–16.3) 0.5898
Sex, no. (%) 0.0916
Male 33 (72%) 183 (56%)
Female 13 (28%) 147 (44%)
Site, no. (%) 0.2810
Head and neck 10 (22%) 35 (14%)
Trunk 12 (26%) 81 (32%)
Legs 19 (41%) 79 (32%)
Arms 10 (22%) 48 (19.2%)
Others3 0 7 (3%)
Not available 0 80
Melanoma type, no. (%) 0.5897
Superficial spreading melanoma 28 (61%) 88 (64%)
Nodular melanoma 8 (17%) 26 (19%)
Acrolentiginous melanoma 3 (7%) 7 (5%)
Lentigo maligna melanoma 1 (2%) 2 (2%)
Desmoplastic melanoma 1 (2%) 1 (1%)
Nevoid melanoma 0 1 (1%)
MIS 2 (4%) 0
Unclassified 0 0
Others4 3 (7%) 12 (9%)
Not available 0 193
AJCC stage at diagnosis 0.2390
0 2 (4%) 0
I 10 (22%) 191 (69%)
II 16 (36%) 11 (4%)
III 18 (40%) 60 (22%)
IV 0 14 (5%)
Not available 0 54
Ulceration, no. (%) 0.2516
Absent 28 (61%) 83 (61%)
Present 18 (39%) 54 (39%)
Not available 0 193
Mitotic rate, no. per mm2 —
0 13 (28%) —
1–6 19 (41%) —
46 13 (31%) —
Not available 0 330
Median follow-up, days 875 1,602 o0.0001
Abbreviation: AJCC, American Joint Committee on Cancer.
1The characteristics are presented for primary melanomas only.
2Age of the patients calculated at the first biopsy.
3Oral, male genital, and female vaginal location.
4Polypoid, mucosal melanoma, spindle-cell melanoma, Spitz-type mela-
noma, and amelanotic melanoma.
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levels of HMGA2 as high (above the median 6.29) and low
(below the median). Multivariate analysis demonstrated a
significant association of HMGA2 overexpression (X6.29)
with regional (OR¼ 10.0, 95% CI¼1.5–66.6, P¼0.0176)
and distant metastases (OR¼6.8, 95% CI¼1.2–39.0,
P¼0.0318) after adjusting for American Joint Committee on
Cancer (AJCC) stage and age at diagnosis. Survival analysis
showed that expression of HMGA2 above the median was
significantly associated with DFS (hazard ratio (HR)¼ 6.3,
95% CI¼1.8–22.3, P¼ 0.004), OS (stratified log-rank
P¼0.008), and distant metastases–free survival (DMFS)
(HR¼ 6.4, 95% CI¼ 1.4–29.7, P¼0.018) after adjusting for
AJCC stage and age at diagnosis (Figure 3a). Immunohisto-
chemical staining against HMGA2 was also associated with
DFS after adjusting for AJCC stage and age at diagnosis
(HR¼ 4.8, 95% CI¼ 1.25–18.1, P¼ 0.0221) (Figure 3b).
Leave-five-out cross-validation confirmed these results, with
a mean HR of 6.76 for DFS (99.9% of resamples with Po0.05)
and a mean HR of 7.12 for DMFS across the 1,000 replicates
(90.8% of resamples with Po0.05).
HMGA2 expression and melanoma survival in an independent
melanoma replication set
An independent replication tissue microarray (TMA) compris-
ing 580 melanomas (Gould Rothberg et al., 2009a) was used
to replicate the association of HMGA2 expression with
survival. Only OS was analyzed because data regarding
local recurrence and regional metastases were not available.
HMGA2 expression was evaluated using AQUA scores.
Although 506 passed quality control, survival data were
available for only 330 melanomas.
To estimate OS in the replication TMA, we compared
survival between melanomas with 75% quartile of HMGA2
expression measured by AQUA to 25% quartile. We found
significant association of HMGA2 overexpression with
reduced OS of melanoma patients after adjustment for AJCC
stage and age at diagnosis (HR¼1.72, 95% CI¼ 1.09–2.73,
P¼0.0211) (Figure 4).
DISCUSSION
Our study used fresh frozen tissue from patients with newly
diagnosed melanoma to compare gene expression and identify
new melanoma-associated genes. Some of the previous
melanoma expression studies used tissue samples (Haqq
et al., 2005; Talantov et al., 2005; Mandruzzato et al.,
2006; Winnepenninckx et al., 2006; Conway et al., 2009),
but the majority of studies used cell lines. Although fresh tissue
analysis is a strength of our study, relatively small sample size
and a large number of melanomas with Breslow depth
42 mm limit generalization of our findings. We tried to
address this issue by replicating our results in an
independent melanoma set.
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Figure 1. Expression of HMGA2 in normal skin, primary melanoma, and melanoma metastases. (a) Overexpression of HMGA2 probe 208025_s_at was
considered above the median (6.29). Orange–gray bar represents primary melanomas that metastasized later (orange). BRAF mutations are shown in yellow and
NRAS mutants are showed in blue bars. (b) Pearson correlation between microarray and quantitative PCR HMGA2 expression data (0.84, Po0.0001).
(c) Correlation between HMGA2 expression data from microarray and nuclear immunohistochemistry (IHC) intensity staining against HMGA2 (neg, negative
staining; posþ , moderate intensity; posþ þ , strong intensity).
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Figure 2. Representative sections with immunohistochemical staining against
HMGA2. (a, b) Normal skin and benign nevus have no nuclear staining,
(c, d) whereas both primary melanoma (diffuse) and melanoma metastases
(patchy) have strong nuclear staining against HMGA2. Bar¼50mm.
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Figure 4. Kaplan–Meier curves for overall survival associated with the
expression of HMGA2 protein in an independent set of 330 melanomas.
HMGA2 expression was studied in melanoma tissue microarray (TMA) and
analyzed by AQUA. HMGA2 expression was compared between 75% quartile
(red) and in 25% quartile (blue). Overall survival was analyzed using stratified
multivariate log-rank test including age at diagnosis and American Joint
Committee on Cancer stage. HMGA2 overexpression was significantly
associated with reduced overall survival of melanoma patients (hazard
ratio¼ 1.72, P¼ 0.0211).
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Gene lists generated by our study include both well-known
melanoma genes and novel genes that have not previously
been reported in relation to melanoma development. One of
the new genes is a transcription factor HMGA2 that was
significantly upregulated in both primary melanoma and MM
(P-values¼1.2 10 7 and 9 10 5) compared with N.
Moreover, HMGA2 overexpression in primary melanoma
was significantly associated with survival of melanoma
patients, probably explained by the increased metastatic
potential of HMGA2-expressing tumors. The oncogene
HMGA2 is an embryonic architectural transcription factor
that is completely silenced or undetectable in normal adult
tissues, but has a significant role in the transformation of many
cancer types (Miyazawa et al., 2004; Meyer et al., 2007;
Malek et al., 2008). HMGA2 binds to the minor groove of
DNA in AT-rich regions using AT-hook sequences, changes
DNA conformation, and facilitates binding of other
transcription factors (Reeves, 2001). The oncogenic role of
HMGA2 has not been previously recognized in the
pathogenesis of melanoma. However, HMGA2 has been
well documented in other types of cancer, where it can be
overexpressed, amplified, or fused with other proteins (Fusco
and Fedele, 2007).
A large study examining gene expression in 83 PCMs
identified a 254-gene prognostic signature, but HMGA2
was not among these genes (Winnepenninckx et al., 2006).
Re-examination of the data shows that HMGA2 was indeed
associated with melanoma thickness, supporting our
conclusion about biological relevance of HMGA2 in
melanoma. Another study of nine melanoma cell lines
demonstrated 2.96-fold overexpression of HMGA2
compared with normal human melanocytes (Hoek et al.,
2004). Contributing to previously published transcriptome
studies of melanoma, our results offer new insights into the
pathogenesis of melanoma by highlighting the differential
expression and prognostic importance of HMGA2.
Several mechanisms may underlie the oncogenicity of
HMGA2, including the activation of transcription factor
E2F1 through binding of HMGA2 to pRB (Fedele et al.,
2006), direct or indirect induction of cyclin A (Pagano et al.,
1992), or negative regulation of nucleotide excision repair
genes (Borrmann et al., 2003). The chemokine CXCL1, which
is overexpressed in melanoma and is involved in melanoma
progression, has been shown to be regulated by HMGA2
(Nirodi et al., 2001). It is noteworthy that both CXCL1
and HMGA2 were significantly overexpressed in melanoma
in our study. TGF-beta mediates epithelial–mesenchymal
transition by inducing HMGA2 through the SMAD pathway,
which may partially explain the association between HMGA2
overexpression and MM in our study (Thuault et al., 2006).
HMGA2 also enhances the NF-kB complex formation
(Noro et al., 2003).
HMGA2 expression is negatively regulated by the miRNA
let-7 family (Peng et al., 2008). Loss of expression of let-7
increases the expression of c-Myc, RAS, CDK4, integrin-b(3),
and HMGA2 (Johnson et al., 2005; Park et al., 2007; Muller
and Bosserhoff, 2008; Schultz et al., 2008). Clusters of let-7a-
1_let-7f-1_let-7d are located in 9p22.3, which is deleted in
81% of cases of cutaneous melanoma (Bastian et al., 1998).
The MAPK pathway, activated by BRAF/NRAS mutations,
negatively regulates let-7 by inducing LIN28 expression
through Myc transcription (Dangi-Garimella et al., 2009).
This mechanism may explain the association of HMGA2
overexpression with BRAF/NRAS mutations in our study. A
recent study showed that let-7 is downregulated in highly
invasive melanoma cell lines (Mueller et al., 2009).
Activated oncogenes in normal cells trigger senescence as a
key protective mechanism against cancer (Mooi and Peeper,
2006). For example, INK4/ARF products are essential
activators of p53-dependent and p53-independent melano-
cyte senescence (Bennett and Medrano, 2002). In addition,
oncogenic BRAF and NRAS can induce p16 expression and
senescence in melanocytes in vitro (Gray-Schopfer et al.,
2006). During melanoma progression, c-Myc overexpression
continuously suppresses BRAF*V600E- and NRAS*Q61R-
dependent senescence programs, independently of p16 and
p53 senescence mechanisms (Zhuang et al., 2008).
HMGA2 is also required for normal proliferation and self-
renewal of fetal and young adult neural stem cells through
repression of the INK4/ARF locus; however, during aging,
let7b blocks HMGA2 and contributes to declining neural stem
cell function (Tzatsos and Bardeesy, 2008). We speculate that
BRAF- and NRAS-activated senescence is overridden by both
p16- and p53-independent c-Myc overexpression and by
HMGA2 repression of p16- and p53-induced apoptosis and
cell senescence. It is noteworthy that HMGA2 is directly
regulated by c-Myc (Wood et al., 2000).
Overexpressed HMGA2 correlates with amplification of
12q harboring HMGA2 in gastric cancer, liposarcoma, and
carcinoma ex pleomorphic adenoma (Yang et al., 2007;
Persson et al., 2009). This correlation was associated with
copy number variability in other tumor suppressor genes and
oncogenes (MDM2 and CDK4), showing a specific pattern in
tumor subtypes.
HMGA2 analysis may have some important clinical appli-
cations. Observational noninvasive clinical trials are needed
to further estimate the prognostic value of HMGA2 expression
in melanoma. Although immunohistochemistry and quantita-
tive PCR are still the methods of choice, recent improvements
in next-generation sequencing technology may introduce
targeted RNAseq for routine testing of HMGA2 expression
in melanoma. The melanoma patients with overexpressed
HMGA2 might benefit from more aggressive treatment and
closer follow-up. In addition, HMGA2 may be a potential
therapeutic target, as HMGA2 expression seems to be non-
essential for normal cell survival, and therapeutic gene
silencing would be relatively safe. This approach has been
successful in ovarian carcinoma, where short-hairpin RNA
silencing of HMGA2 inhibited cell proliferation, with G1 cell
cycle arrest and increased apoptosis in vitro, as well as tumor
growth inhibition in vivo (Malek et al., 2008).
Our study highlights a new aspect of melanoma biology by
implicating the well-known oncogene HMGA2 in melanoma
progression. We propose that HMGA2 has an important role
in melanoma development and serves as an independent
prognostic factor. Further studies of HMGA2 in melanoma are
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warranted to better understand its role in melanoma develop-
ment and progression.
MATERIALS AND METHODS
Tissue samples
Our report was written to comply with REMARK criteria (McShane
et al., 2005; Gould Rothberg et al., 2009b); therefore, we provide
relevant information about study design, hypotheses, patient and
specimen characteristics, assay methods, and statistical analysis
methods. In addition, we conducted a replication study.
Frozen cutaneous melanomas were obtained from the University of
Michigan Multidisciplinary Melanoma Clinic where 7,959 patients
were treated from 2002 through 2008. The study has been approved
by the institutional review board. Samples were selected from 421
frozen primary or metastatic samples including pediatric and non-
Caucasian cases consecutively collected during this period. All
participating patients received standard-of-care treatment with surgi-
cal excision of lesions. OS, DFS, and DMFS data were collected from
chart reviews, University of Michigan Cancer Tumor Registry, and by
communication with the patient or his/her family. OS was confirmed
using the National Death Index.
Detailed description of sample preparation, isolation of RNA, DNA
and microarray hybridization, as well as mutational analysis, quanti-
tative RT-PCR, and immunohistochemistry, can be found in
Supplementary Methods online.
For independent replication of survival analysis, we obtained well-
annotated melanoma TMA slides from Dr David L Rimm (Yale
University) comprising 580 primary melanomas and MM. The
available de-identified data included clinicopathological features,
OS, and demographic characteristics.
Statistical analysis
Microarray expression data were analyzed using Bioconductor for R
(Gentleman et al., 2004). Detailed description of statistical analysis of
the expression microarray can be found in Supplementary Materials
online.
Kaplan–Meier survival curves and log-rank tests were used to
analyze OS, DFS (without local recurrence, regional, or distant
metastases), and DMFS. Multivariate Cox proportional hazard regres-
sion model was adjusted for AJCC stage (stages I/ II vs. stage III)
and age at diagnosis. Wald tests based on maximum likelihood
estimates of the log-HR parameters in the Cox model were deemed
significant at Po0.05. OS was evaluated by the stratified log-rank test
adjusted for AJCC stage and age at diagnosis because of sparsity of
events. Leave-five-out cross-validation (1,000 random permutations
of 46 melanomas) evaluated the consistency and robustness of the
survival analysis. We use multivariate logistic regression to estimate
the association between HMGA2 expression and metastases, and
linear regression for the association between HMGA2 expression and
BRAF/NRAS mutations. All analyses were performed in SAS 9.1 (SAS
Institute, Cary, NC) using FREQ, LIFETEST, PHREG, and LOGISTIC.
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